nov8k.htm




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):
November 9, 2009

ANTARES PHARMA, INC.
(Exact name of registrant specified in its charter)
Delaware
1-32302
41-1350192
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
250 Phillips Blvd., Suite 290, Ewing, NJ
08618
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone, including area code:
(609) 359-3020
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

□           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
□           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
□           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
□           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 

Item 2.02 Results of Operations and Financial Condition.
 
On November 9, 2009, Antares Pharma, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its third fiscal quarter ended September 30, 2009.
 
A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit 99.1
  
Press Release, dated November 9, 2009.


 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
ANTARES PHARMA, INC.
   
Date:
November 9, 2009
By:     
/s/ Paul K. Wotton
 
Name:   Dr. Paul K. Wotton
Title:     President and Chief Executive Officer



 
 
 

EXHIBIT INDEX


 

Exhibit No.
  
Description
Exhibit 99.1
  
Press Release, dated November 9, 2009.